Methods comprising apoptosis inhibitors for the generation of transgenic pigs |
 |
|
|
||||||||||||||||||||||||||||||||||||||||||
| Title: | Infusion of neutrophil precursors for treatment of neutropenia |
| Inventors: | Smith, Stephen L.; Arlington Heights, IL, USA Qiao, Xiaoying; Waukegan, IL, USA Maciukas, SUSA n M.; El Cerrito, CA, USA Loudovaris, Maureen F.; Grayslake, IL, USA Bender, James G.; Lindenhurst, IL, USA Van Epps, Dennis E.; Cary, IL, USA |
| Summary: | Described herein are methods of treating a human patient having a reduced neutrophil count by administration of neutrophil precursors in a serum-free and animal protein-free cell suspension. The invention relates to a method of treatment following myeloablative cancer therapy such as high dose chemotherapy. Further disclosed are properties of the cell medium such that it contains at least 25% neutrophil precursors including promyelocytes, myelocytes, and metamyelocytes, and such that the composition is administered to the patient following myeloablative therapy, after which the neutrophil precursors differentiate rapidly in vivo to replenish the supply of mature neutrophils, thereby stimulating the patient’s immunological capacity to fight infection. Claims of the invention include a reduction in the neutropenic window that exists between the time of myeloablative therapy and the time required for infused stem cells to proliferate and differentiate into mature neutrophils. |
| Abstract: | The invention provides a method of treating a patient having a reduced population of neutrophils following a myeloablative cancer treatment such as high dose chemotherapy. Following myeloablative therapy, a cell composition of at least 25% neutrophil precursors, i.e. promyelocytes, myelocytes, and metamyelocytes, is administered to the patient. Thereafter, the neutrophil precursors differentiate rapidly in vivo to replenish the supply of mature neutrophils for fighting infection. The method is used to reduce the neutropenic window between the time of myeloablative therapy and the time required for infused stem cells to proliferate and differentiate into mature neutrophils. |
| US Patent Website: | Click Here for Full Text of Patent |
| Title Number: | US6010697 |
| Application Number: | US1998000141441 |
| Date Filed: | 27/08/1998 |
| Date Published: | 04/01/2000 |
| Assignee: | Nexell Therapeutics, Inc., Irvine, CA, USA |